Results 131 to 140 of about 2,519,772 (150)

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial [PDF]

Lancet, The, 2019
BACKGROUND Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results
Benedetta Terziroli Beretta-Piccoli, David Sheridan, Karen Krok   +2 more
exaly   +8 more sources

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial [PDF]

Lancet, The, 2015
BACKGROUND: The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease.
James A. Tonascia, Mark Van Natta
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

A novel LC-MS/MS method for simultaneous estimation of obeticholic acid, glyco-obeticholic acid, tauro-obeticholic acid in human plasma and its application to a pharmacokinetic study

Journal of Separation Science, 2021
Naresh Kumar Katari, Anand Krishnan, Rambabu Gundla   +2 more
exaly  

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis

Clinical Gastroenterology and Hepatology, 2022
Vlad Ratziu
exaly  

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Gastroenterology, 2022
Richard Sturgess, Aftab Ala, Bettina Hansen   +2 more
exaly  

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Journal of Hepatology, 2023
Philip Newsome, Eric Lawitz, Quentin M Anstee   +2 more
exaly  

Obeticholic acid for the treatment of nonalcoholic steatohepatitis

Expert Review of Gastroenterology and Hepatology, 2020
Kris V. Kowdley
exaly  

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Gastroenterology, 2013
Hanns-Ulrich Marschall, Linda Morrow
exaly  

FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid

Gastroenterology, 2018
Luciano Adorini, Chunyu Zhao
exaly  

Obeticholic acid may increase the risk of gallstone formation in susceptible patients

Journal of Hepatology, 2019
Anders Thorell, Hanns-Ulrich Marschall, Michael Trauner   +2 more
exaly